Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 47 for:    test | ( Map: Gambia )

Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00944840
Recruitment Status : Completed
First Posted : July 23, 2009
Last Update Posted : January 26, 2017
Sponsor:
Information provided by (Responsible Party):
Brian Greenwood, London School of Hygiene and Tropical Medicine

Brief Summary:
Malaria in African countries remains an important cause of mortality and morbidity among young children. The global malaria control strategies include prompt treatment with an effective antimalarial drug, vector control using ITNs or curtains, indoor residual spraying (IRS), and intermittent preventive treatment. However, individually these interventions provide only imperfect protection. Thus, there is a need to investigate whether additional control measures provide added benefit in reducing mortality and morbidity. Therefore, 1312 children under 5 years of age living in villages and hamlets near Farafenni, The Gambia, which form part of the rural Farafenni Demographic Surveillance system (FDSS) in North Bank Region(NBR) were randomly allocated to receive IPTc or placebo from village health workers based in primary health care villages. Treatment with a single dose of sulfadoxine /pyrimethamine plus three doses of amodiaquine or placebo was given to all study subjects at monthly intervals on three occasions during the months of September, October and November. In addition, VHWs were trained to administer treatment with coartem to children if they develop symptoms compatible with malaria during the malaria transmission season. The primary end point was the incidence of clinical attacks of malaria detected during the study.

Condition or disease Intervention/treatment Phase
Malaria Drug: SP plus amodiaquine Drug: SP placebo plus amodiaquine placebo Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1312 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia
Study Start Date : September 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Active Comparator: SP and amodiaquine
Study subjects received intermittent preventive treatment with SP plus amodiaquine.
Drug: SP plus amodiaquine
SP plus amodiaquine or placebo at monthly interval during September, October and November
Other Names:
  • Camoquin
  • Fansidar

Placebo Comparator: SP placebo plus amodiaquine placebo
Intermittent preventive treatment with SP placebo and amodiaquine placebo
Drug: SP placebo plus amodiaquine placebo
monthly treatment with amodiaquine and SP or placebo during September, October and November




Primary Outcome Measures :
  1. Malaria incidence (the number of study subjects seen at the OPD clinic with clinical malaria during the surveillance period). [ Time Frame: During the surveillance period (September to December 2008) ]

Secondary Outcome Measures :
  1. prevalence of parasitaemia at the end of malaria transmission season in December 2008 [ Time Frame: December 2008 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   3 Months to 59 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age between 3 months and 59 months at enrolment.
  2. Informed consent obtained from parents or legal guardians.
  3. No current participation in another malaria intervention trial
  4. Permanent residence in the study area with no intention of leaving during the surveillance period.

Exclusion Criteria:

  1. Previous adverse reaction to treatment with SP, amodiaquine or Coartem. If this is unknown, then a history of allergic reaction to any drug.
  2. Temporary residence in the study area
  3. Lack of informed consent
  4. Presence of a severe, chronic illness such as severe malnutrition or AIDS, likely to interfere with evaluation of the trial results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944840


Locations
Layout table for location information
Gambia
Farafenni Field Station, MRC Laboratories
Farafenni, North Bank Region, Gambia
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
Investigators
Layout table for investigator information
Principal Investigator: Kalifa Bojang, MD, PhD MRC Laboratories

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Brian Greenwood, Professor, London School of Hygiene and Tropical Medicine
ClinicalTrials.gov Identifier: NCT00944840     History of Changes
Other Study ID Numbers: SCC 1124
First Posted: July 23, 2009    Key Record Dates
Last Update Posted: January 26, 2017
Last Verified: January 2017

Keywords provided by Brian Greenwood, London School of Hygiene and Tropical Medicine:
Intermittent Preventive Treatment
Home based management of malaria

Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases
Amodiaquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents